^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    TAS1553

    i
    Other names: TAS1553, TAS 1553
    Associations

    News

    Trials
    Company:
    Otsuka
    Drug class:
    Ribonucleotide reductase inhibitor
    Related drugs:
    Associations

    News

    Trials
    11ms
    A Study of TAS1553 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML) and Other Myeloid Neoplasms (clinicaltrials.gov)
    P1, N=20, Terminated, Astex Pharmaceuticals, Inc. | Trial completion date: Aug 2023 --> Feb 2023 | Active, not recruiting --> Terminated | Trial primary completion date: Aug 2023 --> Feb 2023; termination due to portfolio prioritization
    Trial completion date • Trial termination • Trial primary completion date
    |
    TAS1553
    almost2years
    TAS1553, a small molecule subunit interaction inhibitor of ribonucleotide reductase, exhibits antitumor activity by causing DNA replication stress. (PubMed, Commun Biol)
    Oral administration of TAS1553 demonstrated robust antitumor efficacy against both hematological and solid cancer xenograft tumors and also provided a significant survival benefit in an acute myelogenous leukemia model. Our findings strongly support the evaluation of TAS1553 in clinical trials.
    Journal
    |
    SLFN11 (Schlafen Family Member 11)
    |
    TAS1553
    over3years
    A Study of TAS1553 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML) and Other Myeloid Neoplasms (clinicaltrials.gov)
    Not yet recruiting --> Recruiting
    Clinical • Enrollment open
    |
    CHEK1 (Checkpoint kinase 1)
    |
    TAS1553